NZ795026A - Administration of cebp-beta antagonist and methods of use - Google Patents

Administration of cebp-beta antagonist and methods of use

Info

Publication number
NZ795026A
NZ795026A NZ795026A NZ79502621A NZ795026A NZ 795026 A NZ795026 A NZ 795026A NZ 795026 A NZ795026 A NZ 795026A NZ 79502621 A NZ79502621 A NZ 79502621A NZ 795026 A NZ795026 A NZ 795026A
Authority
NZ
New Zealand
Prior art keywords
methods
cebp
administration
beta antagonist
εβρβ
Prior art date
Application number
NZ795026A
Other languages
English (en)
Inventor
Barry Kappel
Gene Merutka
Jimmy Rotolo
Robert E Michel
Alice Susannah Bexon
Original Assignee
Sapience Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapience Therapeutics Inc filed Critical Sapience Therapeutics Inc
Publication of NZ795026A publication Critical patent/NZ795026A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ795026A 2020-06-21 2021-06-21 Administration of cebp-beta antagonist and methods of use NZ795026A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063041989P 2020-06-21 2020-06-21
US202063041986P 2020-06-21 2020-06-21
US202063041988P 2020-06-21 2020-06-21
US202063041990P 2020-06-21 2020-06-21
US202063041991P 2020-06-21 2020-06-21
US202163172560P 2021-04-08 2021-04-08
PCT/US2021/038264 WO2021262604A2 (en) 2020-06-21 2021-06-21 Administration of cebp-beta antagonist and methods of use

Publications (1)

Publication Number Publication Date
NZ795026A true NZ795026A (en) 2026-03-27

Family

ID=79281738

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ795026A NZ795026A (en) 2020-06-21 2021-06-21 Administration of cebp-beta antagonist and methods of use

Country Status (14)

Country Link
US (1) US20230218717A1 (https=)
EP (1) EP4168033B1 (https=)
JP (1) JP2023531683A (https=)
KR (1) KR20230027054A (https=)
CN (1) CN115768458A (https=)
AU (1) AU2021297172B2 (https=)
BR (1) BR112022025880A2 (https=)
CA (1) CA3180559A1 (https=)
FI (1) FI4168033T3 (https=)
IL (1) IL299104A (https=)
MX (1) MX2022016478A (https=)
NZ (1) NZ795026A (https=)
PT (1) PT4168033T (https=)
WO (1) WO2021262604A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025532391A (ja) * 2022-10-07 2025-09-29 サピエンス・セラピューティクス・インコーポレーテッド Ｃ／ｅｂｐ－ベータアンタゴニスト及び免疫調節剤の使用
WO2024216238A2 (en) * 2023-04-13 2024-10-17 Sapience Therapeutics, Inc. Use of beta-catenin antagonist and immunomodulator
AU2024252321A1 (en) * 2023-04-13 2025-10-16 Sapience Therapeutics, Inc. Administration of a beta-catenin antagonist and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016516669A (ja) * 2013-02-22 2016-06-09 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 転写因子ａｔｆ５の阻害により腫瘍細胞を阻害するための組成物および方法
US10899834B2 (en) * 2015-04-16 2021-01-26 H. Lundbeck A/S Anti-PACAP antibodies
WO2018152446A2 (en) * 2017-02-20 2018-08-23 Sapience Therapeutics, Inc. Cell-penetrating atf5 polypeptides and uses thereof
WO2019136125A1 (en) * 2018-01-03 2019-07-11 Sapience Therapeutics, Inc. Atf5 peptide variants and uses thereof
WO2020033555A2 (en) * 2018-08-08 2020-02-13 The Trustees Of Columbia University In The City Of New York Dominant negative cebpb and cebpd proteins and methods of use for decreasing viability of neoplastic cells

Also Published As

Publication number Publication date
WO2021262604A3 (en) 2022-02-17
CN115768458A (zh) 2023-03-07
KR20230027054A (ko) 2023-02-27
FI4168033T3 (fi) 2026-04-07
JP2023531683A (ja) 2023-07-25
BR112022025880A2 (pt) 2023-01-10
EP4168033B1 (en) 2026-02-25
US20230218717A1 (en) 2023-07-13
EP4168033A2 (en) 2023-04-26
AU2021297172A1 (en) 2023-01-19
CA3180559A1 (en) 2021-12-30
AU2021297172B2 (en) 2025-01-30
EP4168033A4 (en) 2024-06-19
IL299104A (en) 2023-02-01
PT4168033T (pt) 2026-03-24
MX2022016478A (es) 2023-02-01
WO2021262604A2 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
NZ795026A (en) Administration of cebp-beta antagonist and methods of use
PH12019502621A1 (en) Antibody-cytokine engrafted proteins and methods of use in the treatement of cancer
MX2023014059A (es) Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante.
SA521421973B1 (ar) عامل مضاد لمستقبل crf1، ومستحضرات صيدلانية وأشكال صلبة منها لعلاج فرط التنسج الكظري الخلقي
MX2022009100A (es) Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de cancer.
Wang et al. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia
WO2021222150A3 (en) Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
FI3463436T3 (fi) Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää
MX2023006419A (es) Compuestos polipéptidos modificados con lactama.
MX2025008834A (es) Proteinas de fusion anti-pd-1/il-2, composiciones farmaceuticas y aplicaciones terapeuticas
JP2023036860A (ja) 腫瘍浸潤ｔ細胞集団を生成する方法
MX2024012582A (es) Composiciones farmaceuticas de proteinas terapeuticas y metodos de uso
US20210379046A1 (en) Methods of Treating Diseases Using Kinase Modulators
WO2023023588A3 (en) Methods and compositions of inhibiting asprosin mediated orexigenesis and/or glucogenesis
JOP20230150A1 (ar) صيغ ببتيد علاجية
MX2025007357A (es) Proteinas de union anti-pd-1?4-1bb
WO2022020648A9 (en) Inhibitors of the artemin pathway for treatment of cancer
US11628204B2 (en) Preventing cytokine release syndrome
EA202092530A1 (ru) Способы облегчения старческой астении и старения
MX2021004603A (es) Dosificacion.
EA202192094A1 (ru) Аналог агониста глюкагоноподобного пептида-1 (glp-1), способ его получения и применение
MX2025012127A (es) Administracion de un antagonista de beta-catenina y metodos de uso
MX2025004062A (es) Uso de un antagonista de c/ebp-beta y un inmunomodulador
SA520420147B1 (ar) ("tcd") مثبطات إفراز بروتين أساسها تراي أزا سيكلو دوديكان سلفوناميد
CL2021003497A1 (es) Composiciones farmacéuticas para péptidos co-agonistas de glucagón y glp-1